Focus Partners Wealth
LTRN icon

Focus Partners Wealth’s Lantern Pharma LTRN Stock Holding History

Focus Partners Wealth’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.4K Hold
15,432
– – ﹤0.01% 2662
2026
Q1 		$21.1K Sell
15,432
-550
-3% -$1.54K ﹤0.01% 2610
2025
Q4 		$48.4K Buy
+15,982
New +$59.5K ﹤0.01% 2606

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Focus Partners Wealth's LTRN Position: Q2 2026 in Review

Focus Partners Wealth held its Lantern Pharma (LTRN) position steady in Q2 2026 at 15,432 shares worth $64.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

Focus Partners Wealth first reported a position in LTRN in Q4 2025 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Focus Partners Wealth held 15,432 shares of Lantern Pharma worth $64.4K as of Q2 2026.
  • Focus Partners Wealth left its Lantern Pharma share count unchanged in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2662 holding.
  • Focus Partners Wealth first reported a position in Lantern Pharma in Q4 2025 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.